Grant Matthew Fischer, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 7 | 2023 | 5194 | 0.850 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2020 | 443 | 0.750 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1060 | 0.470 |
Why?
|
Oxidative Phosphorylation | 3 | 2020 | 489 | 0.350 |
Why?
|
Tumor Microenvironment | 3 | 2020 | 2987 | 0.330 |
Why?
|
Brain Neoplasms | 4 | 2021 | 8776 | 0.300 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 2 | 2019 | 192 | 0.290 |
Why?
|
Oxadiazoles | 2 | 2020 | 93 | 0.250 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5266 | 0.220 |
Why?
|
Glutaminase | 1 | 2020 | 32 | 0.210 |
Why?
|
DNA Fingerprinting | 1 | 2021 | 117 | 0.210 |
Why?
|
Phosphoglycerate Dehydrogenase | 1 | 2020 | 37 | 0.200 |
Why?
|
Databases, Nucleic Acid | 1 | 2020 | 216 | 0.190 |
Why?
|
Tissue Array Analysis | 1 | 2020 | 580 | 0.180 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 985 | 0.140 |
Why?
|
Piperidines | 2 | 2020 | 1582 | 0.140 |
Why?
|
Amino Acid Substitution | 1 | 2019 | 1823 | 0.130 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 3714 | 0.130 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9556 | 0.120 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 185 | 0.110 |
Why?
|
Metabolome | 1 | 2019 | 859 | 0.110 |
Why?
|
Mice, Nude | 1 | 2019 | 3859 | 0.110 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 1588 | 0.110 |
Why?
|
Up-Regulation | 1 | 2020 | 4353 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8638 | 0.100 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6571 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2040 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2593 | 0.100 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 730 | 0.090 |
Why?
|
Mice | 8 | 2021 | 80876 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11790 | 0.070 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2165 | 0.070 |
Why?
|
Animals | 9 | 2021 | 170486 | 0.070 |
Why?
|
Actins | 1 | 2013 | 2191 | 0.070 |
Why?
|
Genomics | 1 | 2021 | 5300 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2011 | 1309 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18375 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16959 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5405 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10362 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2971 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 4865 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 5197 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22989 | 0.050 |
Why?
|
Prognosis | 1 | 2020 | 28919 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11253 | 0.040 |
Why?
|
Protein Array Analysis | 1 | 2021 | 412 | 0.040 |
Why?
|
Humans | 11 | 2023 | 708843 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2021 | 607 | 0.040 |
Why?
|
Proteomics | 2 | 2021 | 3244 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2020 | 745 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13714 | 0.040 |
Why?
|
Glycine | 1 | 2020 | 693 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2011 | 3956 | 0.040 |
Why?
|
Serine | 1 | 2020 | 852 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2020 | 12183 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 39292 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2021 | 2673 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1728 | 0.030 |
Why?
|
Mass Screening | 1 | 2011 | 5182 | 0.030 |
Why?
|
Mice, SCID | 1 | 2021 | 2835 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 1894 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23950 | 0.030 |
Why?
|
Brain | 1 | 2020 | 24969 | 0.030 |
Why?
|
Protein Kinases | 1 | 2019 | 1680 | 0.030 |
Why?
|
Metabolomics | 1 | 2020 | 1357 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2205 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2011 | 313 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3693 | 0.030 |
Why?
|
Cell Survival | 1 | 2021 | 6156 | 0.020 |
Why?
|
Female | 5 | 2021 | 375205 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2118 | 0.020 |
Why?
|
Hyperplasia | 1 | 2013 | 1182 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2019 | 1922 | 0.020 |
Why?
|
Base Sequence | 1 | 2021 | 13352 | 0.020 |
Why?
|
Phosphorylation | 1 | 2019 | 8720 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10507 | 0.020 |
Why?
|
Protein Transport | 1 | 2013 | 2059 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4254 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3879 | 0.020 |
Why?
|
Mitochondria | 1 | 2019 | 3665 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
Immunotherapy | 1 | 2020 | 4057 | 0.020 |
Why?
|
Body Mass Index | 1 | 2023 | 12366 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2013 | 3021 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6170 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12031 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5489 | 0.010 |
Why?
|
Caregivers | 1 | 2011 | 1906 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2013 | 15274 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2013 | 10803 | 0.010 |
Why?
|
Models, Biological | 1 | 2013 | 9907 | 0.010 |
Why?
|
Risk Factors | 1 | 2023 | 69553 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14836 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 16306 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 7428 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 23020 | 0.010 |
Why?
|
Prospective Studies | 1 | 2011 | 50597 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2011 | 58184 | 0.000 |
Why?
|
Aged | 1 | 2011 | 161488 | 0.000 |
Why?
|
Male | 1 | 2011 | 349524 | 0.000 |
Why?
|